Streamlining Cell Line Development for Faster Biologics Production

Efficient cell line development remains one of the most critical challenges in biotherapeutic manufacturing.

Achieving stable, high-yield expression systems while maintaining product quality and regulatory readiness can significantly impact development timelines and overall program success.

This webinar will explore advanced strategies that streamline every stage of cell line development and process optimization, using transposase-based expression technology designed to enable the stable, non-random integration of multiple copies of expression constructs into CHO-K1 cells.

Accelerated development is enabled by the transposase-mediated stable integration that maintains structural integrity, with the stable pool identically expressing product subunits.

A strong productivity and product quality comparability between the pools and the derivative stable clones allowing for the earlier production of representative drug material in quantities suitable for toxicology and preclinical studies.

The featured speakers will also discuss integrated, end-to-end development strategies that accelerate biologics programs targeting complex or previously difficult-to-address antigens.

Through multidisciplinary collaboration across discovery, pharmacology, preclinical and technical development functions, the workflow demonstrates how synchronized CHO cell line and upstream process development can reduce risk, improve tech transfer and enhance scalability.

Beginning with stable pools, this process supports efficient generation of representative material for early safety studies and facilitates alignment between clone selection, process optimization and downstream manufacturing.

Register for this webinar to learn how streamlined cell line development supports faster, more reliable biologics production and smoother transition to clinical manufacturing. 

Speakers

Cláudia Soares, Lead Scientist Drug Substance, CDR-Life

Cláudia is a trained Pharmacist and obtained her MSc from the University of Coimbra, in Portugal. She started her career at a CDMO with a focus on cell line and cell culture development. Cláudia joined the USP team at CDR-Life over two years ago and is now the Lead Scientist in the Drug Substance group. She specializes in developing a USP platform for CDR-Life’s proprietary M-gager® T cell engager format. Leveraging her expertise, Cláudia developed a platform process that ensures smooth process development aligned with cell line development and clinical manufacturing.

Message Presenter

Lynn Webster, Senior Scientist, Cell Line Development, ATUM

Lynn is a seasoned expert in mammalian cell line development. Over the last eight years at ATUM, she has established herself as the go-to expert on all practical aspects of Leap-In technology applications and is a co-author on seminal papers on the use of the platform. Prior to ATUM, she held senior scientist roles at XOMA, where she managed the mammalian cell culture facility, and Berlex Biosciences (now Bayer HealthCare).

Message Presenter